GlassScriptPhysician profile
Betty S Pace
NPI 1700195039
$64,300.26
in general payments reported to CMS, 2019-2025
5 companies · $28K in 2025
The $28K reported for 2025 was more than what 93% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $12.45 · 2021: $140 · 2022: $18.05 · 2023: $18K · 2024: $18K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,960.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $51,219.50 | 2023-2025 | |
| Novo Nordisk Health Care Ag | $10,710.00 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $2,177.33 | 2019-2025 | |
| Global Blood Therapeutics, INC. | $170.24 | 2020-2022 | |
| Novo Nordisk INC | $23.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.